Jabbour E et al. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of > 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). Proc ASCO 2011;Abstract 6507.